Key Insights
The European Sodium-glucose Cotransporter 2 (SGLT2) inhibitor market is poised for significant expansion, driven by increasing prevalence of type 2 diabetes and a growing understanding of the cardiovascular and renal benefits associated with these drugs. The market is currently valued at approximately $1,300 million and is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 9.10% between 2025 and 2033. This expansion is underpinned by a strong pipeline of innovative treatments and a shifting therapeutic landscape that favors SGLT2 inhibitors for their dual action in glycemic control and organ protection. Key drivers include an aging population in Europe, rising obesity rates, and greater clinician and patient awareness of the long-term advantages of SGLT2 inhibitors beyond simple blood sugar reduction, particularly in mitigating the risk of heart failure and chronic kidney disease progression.
Europe Sodium-glucose Cotransporter 2 Industry Market Size (In Billion)
The competitive landscape is dominated by major pharmaceutical players such as Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim, who are actively engaged in research and development and marketing of leading SGLT2 inhibitor brands like Invokana, Jardiance, and Farxiga/Forxiga. Emerging trends indicate a move towards combination therapies and personalized medicine approaches, leveraging the unique benefits of SGLT2 inhibitors for specific patient profiles. While the market exhibits strong growth potential, it is not without its restraints. These may include evolving reimbursement policies, the potential for adverse events, and the development of newer therapeutic classes. However, the sustained clinical evidence supporting the efficacy and safety of SGLT2 inhibitors, coupled with their expanding indications, suggests a predominantly positive outlook for this crucial segment of the European diabetes treatment market.
Europe Sodium-glucose Cotransporter 2 Industry Company Market Share
This comprehensive report delves into the intricate dynamics of the Europe Sodium-glucose Cotransporter 2 (SGLT2) inhibitor market. Covering the historical period from 2019 to 2024, a base year of 2025, and a robust forecast period extending to 2033, this analysis provides critical insights for stakeholders navigating this rapidly evolving sector. The Europe SGLT2 inhibitor market size is projected to experience significant growth, driven by expanding therapeutic indications and increasing adoption for cardiovascular and renal protection, in addition to its established role in diabetes management. We analyze market concentration, innovation, regulatory landscapes, and competitive strategies of key players.
Europe Sodium-glucose Cotransporter 2 Industry Market Structure & Competitive Dynamics
The Europe Sodium-glucose Cotransporter 2 industry exhibits a moderately concentrated market structure, characterized by a few dominant pharmaceutical giants and a growing number of emerging players. Innovation ecosystems are vibrant, with substantial investment in R&D focused on expanding SGLT2 inhibitor applications beyond glycemic control, particularly in cardiovascular diseases (CVD) and chronic kidney disease (CKD). Regulatory frameworks within the European Union, while stringent, have become more favorable for SGLT2 inhibitors due to demonstrated benefits in reducing cardiovascular events and slowing CKD progression. Product substitutes are primarily other drug classes for diabetes management, such as GLP-1 receptor agonists, but SGLT2 inhibitors are increasingly recognized for their pleiotropic effects. End-user trends highlight a growing demand for treatments that address multiple comorbidities. Merger and acquisition (M&A) activities are expected to remain a key strategy for market consolidation and pipeline expansion, with estimated M&A deal values in the multi-billion Euro range.
- Market Concentration: Dominated by a few key players, but with increasing competition.
- Innovation Ecosystems: High R&D spending on new indications and drug formulations.
- Regulatory Frameworks: EU approval pathways are crucial; focus on real-world evidence.
- Product Substitutes: GLP-1 RAs, DPP-4 inhibitors, but SGLT2s offer unique benefits.
- End-User Trends: Preference for treatments addressing comorbidities like heart failure and CKD.
- M&A Activities: Strategic acquisitions and partnerships to enhance market presence and pipelines.
Europe Sodium-glucose Cotransporter 2 Industry Industry Trends & Insights
The Europe Sodium-glucose Cotransporter 2 industry is experiencing a transformative growth trajectory, driven by a confluence of factors. The primary growth driver is the expanding understanding and approval of SGLT2 inhibitors for non-diabetic indications, particularly heart failure with reduced ejection fraction (HFrEF), and increasingly, heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). This label expansion has significantly broadened the addressable market for these innovative drugs. Technological disruptions, while not in the form of new SGLT2 molecules entering the market imminently, lie in the sophisticated clinical trial designs and real-world data collection methods that are validating the long-term benefits and cost-effectiveness of SGLT2 inhibitors. Consumer preferences are shifting towards treatments offering cardioprotective and nephroprotective benefits alongside glycemic control, making SGLT2 inhibitors highly attractive. The competitive dynamics are intensifying as companies leverage their existing SGLT2 portfolios to capture market share in these new therapeutic areas. The CAGR of the Europe SGLT2 inhibitor market is projected to be robust, estimated at approximately 15-20% over the forecast period. Market penetration for SGLT2 inhibitors is steadily increasing, especially in countries with robust healthcare systems and a high prevalence of cardiovascular and renal diseases. The strategic importance of these drugs in managing the growing burden of these conditions is undeniable, further fueling market expansion.
Dominant Markets & Segments in Europe Sodium-glucose Cotransporter 2 Industry
The dominant markets within the Europe Sodium-glucose Cotransporter 2 industry are characterized by countries with high healthcare expenditures, advanced healthcare infrastructure, and a significant burden of type 2 diabetes, cardiovascular diseases, and chronic kidney disease. Germany, the United Kingdom, France, and Italy are leading the market due to their substantial patient populations and well-established reimbursement policies for innovative pharmaceuticals. The Invokana (Canagliflozin), Jardiance (Empagliflozin), and Farxiga/Forxiga (Dapagliflozin) segments are all experiencing substantial growth, with their market dominance influenced by their respective approvals for expanded indications. For instance, Farxiga/Forxiga's recent EU approval for HF across the full spectrum of ejection fraction positions it strongly in the cardiovascular segment. Jardiance also holds significant market share due to its established efficacy in diabetes and its growing role in heart failure management. Invokana continues to be a key player, with ongoing research into its cardiovascular and renal benefits.
- Leading Countries: Germany, United Kingdom, France, Italy, Spain.
- Key Drivers for Dominance:
- Economic Policies: Strong national health insurance schemes and favorable reimbursement landscapes.
- Healthcare Infrastructure: Advanced hospital networks, access to specialists, and robust patient monitoring systems.
- Prevalence of Comorbidities: High rates of type 2 diabetes, cardiovascular diseases, and chronic kidney disease.
- Regulatory Approvals: Timely and comprehensive approvals for expanded indications by national health authorities.
- Physician Prescribing Habits: Increased awareness and adoption of SGLT2 inhibitors for their cardioprotective and nephroprotective effects.
- Segment Dominance Analysis:
- Farxiga/Forxiga (Dapagliflozin): Projected to gain significant traction in the heart failure segment due to its broad indication, impacting its overall market share positively.
- Jardiance (Empagliflozin): Continues to hold a strong position due to its established efficacy in diabetes and its growing footprint in heart failure management.
- Invokana (Canagliflozin): Remains a significant player, with its market share influenced by ongoing clinical evidence supporting its cardiovascular and renal benefits.
Europe Sodium-glucose Cotransporter 2 Industry Product Innovations
Product innovation in the Europe SGLT2 inhibitor market primarily revolves around the expansion of existing drug indications and the exploration of novel therapeutic applications. Companies are leveraging extensive clinical trial data to demonstrate the multifaceted benefits of canagliflozin, empagliflozin, and dapagliflozin beyond glycemic control. These innovations focus on addressing critical unmet needs in cardiovascular and renal disease management, offering a significant competitive advantage and driving market penetration. The development of combination therapies and advanced drug delivery systems are also areas of interest, aimed at improving patient adherence and treatment outcomes.
Report Segmentation & Scope
This report meticulously segments the Europe Sodium-glucose Cotransporter 2 market by key drug compounds. The primary segments analyzed include:
- Invokana (Canagliflozin): This segment details the market size, growth projections, and competitive landscape for Invokana within Europe. Its role in diabetes, cardiovascular, and renal outcomes is a key focus.
- Jardiance (Empagliflozin): This section provides an in-depth analysis of the European market for Jardiance, highlighting its applications in diabetes, heart failure, and chronic kidney disease.
- Farxiga/Forxiga (Dapagliflozin): This segment offers a comprehensive overview of Farxiga/Forxiga's market performance in Europe, with a particular emphasis on its recent approvals for heart failure with various ejection fractions.
Each segment analysis includes current market valuations, projected future growth rates, and an assessment of the competitive dynamics influencing each specific drug's market position.
Key Drivers of Europe Sodium-glucose Cotransporter 2 Industry Growth
The Europe Sodium-glucose Cotransporter 2 industry's growth is propelled by several key drivers. The most significant is the expanding therapeutic indications for SGLT2 inhibitors, particularly for the treatment of heart failure and chronic kidney disease (CKD), irrespective of diabetes status. This broadens their utility and patient base. Secondly, increasing global prevalence of type 2 diabetes and associated cardiovascular and renal comorbidities fuels demand. Thirdly, a growing body of clinical evidence demonstrating the cardioprotective and nephroprotective benefits of SGLT2 inhibitors, supported by landmark clinical trials, is driving physician adoption and influencing prescription patterns. Favorable reimbursement policies in many European nations also play a crucial role in market access and patient uptake.
Challenges in the Europe Sodium-glucose Cotransporter 2 Industry Sector
Despite robust growth, the Europe Sodium-glucose Cotransporter 2 industry faces several challenges. Regulatory hurdles, while generally favorable for approved indications, can slow down the approval of new indications or geographical market entries. Supply chain disruptions, exacerbated by geopolitical events, can impact product availability and cost. Intense competition from other drug classes like GLP-1 receptor agonists, which also offer cardiovascular benefits, presents a challenge for market share. Furthermore, the potential for adverse events, such as genitourinary infections and, though rare, diabetic ketoacidosis, necessitates careful patient selection and monitoring, which can impact physician confidence and prescription volume. The cost-effectiveness of these advanced therapies in certain healthcare systems also remains a point of consideration for payers.
Leading Players in the Europe Sodium-glucose Cotransporter 2 Industry Market
- Janssen Pharmaceuticals
- Eli Lilly
- AstraZeneca
- Bristol Myers Squibb
- Boehringer Ingelheim
Key Developments in Europe Sodium-glucose Cotransporter 2 Industry Sector
- February 2023: AstraZeneca's Forxiga (dapagliflozin) received European Union approval to extend its indication for heart failure with reduced ejection fraction. This crucial expansion now covers patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction.
- March 2022: Eli Lilly and Boehringer Ingelheim secured European Union approval for Jardiance (empagliflozin) as a treatment for heart failure. This significant development followed Jardiance's prior label expansion for treating heart failure in the United States, underscoring its growing role in cardiovascular care.
Strategic Europe Sodium-glucose Cotransporter 2 Industry Market Outlook
The strategic outlook for the Europe Sodium-glucose Cotransporter 2 industry is exceptionally positive, driven by the significant expansion of therapeutic indications beyond diabetes. The increasing recognition of SGLT2 inhibitors as foundational therapies for heart failure and chronic kidney disease presents substantial growth accelerators. Companies are strategically investing in real-world evidence generation and post-marketing studies to further solidify the value proposition of their SGLT2 portfolios. The market potential is further enhanced by the growing burden of these chronic diseases across Europe and the increasing focus on preventative and multi-morbidity management strategies within healthcare systems. Future opportunities lie in exploring further cardiovascular and renal protective benefits, potential use in combination therapies, and leveraging digital health solutions to enhance patient management and adherence.
Europe Sodium-glucose Cotransporter 2 Industry Segmentation
-
1. Drugs
- 1.1. Invokana (Canagliflozin)
- 1.2. Jardiance (Empagliflozin)
- 1.3. Farxiga/Forxiga (Dapagliflozin)
Europe Sodium-glucose Cotransporter 2 Industry Segmentation By Geography
- 1. France
- 2. Germany
- 3. Italy
- 4. Spain
- 5. United Kingdom
- 6. Russia
- 7. Rest of Europe
Europe Sodium-glucose Cotransporter 2 Industry Regional Market Share
Geographic Coverage of Europe Sodium-glucose Cotransporter 2 Industry
Europe Sodium-glucose Cotransporter 2 Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 9.10% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Prevalence of Genitourinary Disorders; Increasing Number of Pipeline Products
- 3.3. Market Restrains
- 3.3.1. Lack of Therapy Compliance; Increasing Advent of Counterfeit Drugs
- 3.4. Market Trends
- 3.4.1. Increasing diabetes prevalence
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Drugs
- 5.1.1. Invokana (Canagliflozin)
- 5.1.2. Jardiance (Empagliflozin)
- 5.1.3. Farxiga/Forxiga (Dapagliflozin)
- 5.2. Market Analysis, Insights and Forecast - by Region
- 5.2.1. France
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. United Kingdom
- 5.2.6. Russia
- 5.2.7. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Drugs
- 6. France Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Drugs
- 6.1.1. Invokana (Canagliflozin)
- 6.1.2. Jardiance (Empagliflozin)
- 6.1.3. Farxiga/Forxiga (Dapagliflozin)
- 6.1. Market Analysis, Insights and Forecast - by Drugs
- 7. Germany Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Drugs
- 7.1.1. Invokana (Canagliflozin)
- 7.1.2. Jardiance (Empagliflozin)
- 7.1.3. Farxiga/Forxiga (Dapagliflozin)
- 7.1. Market Analysis, Insights and Forecast - by Drugs
- 8. Italy Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Drugs
- 8.1.1. Invokana (Canagliflozin)
- 8.1.2. Jardiance (Empagliflozin)
- 8.1.3. Farxiga/Forxiga (Dapagliflozin)
- 8.1. Market Analysis, Insights and Forecast - by Drugs
- 9. Spain Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Drugs
- 9.1.1. Invokana (Canagliflozin)
- 9.1.2. Jardiance (Empagliflozin)
- 9.1.3. Farxiga/Forxiga (Dapagliflozin)
- 9.1. Market Analysis, Insights and Forecast - by Drugs
- 10. United Kingdom Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Drugs
- 10.1.1. Invokana (Canagliflozin)
- 10.1.2. Jardiance (Empagliflozin)
- 10.1.3. Farxiga/Forxiga (Dapagliflozin)
- 10.1. Market Analysis, Insights and Forecast - by Drugs
- 11. Russia Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Drugs
- 11.1.1. Invokana (Canagliflozin)
- 11.1.2. Jardiance (Empagliflozin)
- 11.1.3. Farxiga/Forxiga (Dapagliflozin)
- 11.1. Market Analysis, Insights and Forecast - by Drugs
- 12. Rest of Europe Europe Sodium-glucose Cotransporter 2 Industry Analysis, Insights and Forecast, 2020-2032
- 12.1. Market Analysis, Insights and Forecast - by Drugs
- 12.1.1. Invokana (Canagliflozin)
- 12.1.2. Jardiance (Empagliflozin)
- 12.1.3. Farxiga/Forxiga (Dapagliflozin)
- 12.1. Market Analysis, Insights and Forecast - by Drugs
- 13. Competitive Analysis
- 13.1. Market Share Analysis 2025
- 13.2. Company Profiles
- 13.2.1 Janssen Pharmaceuticals
- 13.2.1.1. Overview
- 13.2.1.2. Products
- 13.2.1.3. SWOT Analysis
- 13.2.1.4. Recent Developments
- 13.2.1.5. Financials (Based on Availability)
- 13.2.2 Eli Lilly
- 13.2.2.1. Overview
- 13.2.2.2. Products
- 13.2.2.3. SWOT Analysis
- 13.2.2.4. Recent Developments
- 13.2.2.5. Financials (Based on Availability)
- 13.2.3 AstraZeneca
- 13.2.3.1. Overview
- 13.2.3.2. Products
- 13.2.3.3. SWOT Analysis
- 13.2.3.4. Recent Developments
- 13.2.3.5. Financials (Based on Availability)
- 13.2.4 Bristol Myers Squibb
- 13.2.4.1. Overview
- 13.2.4.2. Products
- 13.2.4.3. SWOT Analysis
- 13.2.4.4. Recent Developments
- 13.2.4.5. Financials (Based on Availability)
- 13.2.5 Boehringer Ingelheim
- 13.2.5.1. Overview
- 13.2.5.2. Products
- 13.2.5.3. SWOT Analysis
- 13.2.5.4. Recent Developments
- 13.2.5.5. Financials (Based on Availability)
- 13.2.6 7 COMPETITIVE LANDSCAPE7 1 COMPANY PROFILES
- 13.2.6.1. Overview
- 13.2.6.2. Products
- 13.2.6.3. SWOT Analysis
- 13.2.6.4. Recent Developments
- 13.2.6.5. Financials (Based on Availability)
- 13.2.1 Janssen Pharmaceuticals
List of Figures
- Figure 1: Europe Sodium-glucose Cotransporter 2 Industry Revenue Breakdown (Million, %) by Product 2025 & 2033
- Figure 2: Europe Sodium-glucose Cotransporter 2 Industry Share (%) by Company 2025
List of Tables
- Table 1: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 2: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Region 2020 & 2033
- Table 3: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 4: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 5: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 6: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 7: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 8: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 9: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 10: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 11: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 12: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 13: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 14: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 15: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Drugs 2020 & 2033
- Table 16: Europe Sodium-glucose Cotransporter 2 Industry Revenue Million Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Europe Sodium-glucose Cotransporter 2 Industry?
The projected CAGR is approximately 9.10%.
2. Which companies are prominent players in the Europe Sodium-glucose Cotransporter 2 Industry?
Key companies in the market include Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, 7 COMPETITIVE LANDSCAPE7 1 COMPANY PROFILES.
3. What are the main segments of the Europe Sodium-glucose Cotransporter 2 Industry?
The market segments include Drugs.
4. Can you provide details about the market size?
The market size is estimated to be USD 1.30 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Prevalence of Genitourinary Disorders; Increasing Number of Pipeline Products.
6. What are the notable trends driving market growth?
Increasing diabetes prevalence.
7. Are there any restraints impacting market growth?
Lack of Therapy Compliance; Increasing Advent of Counterfeit Drugs.
8. Can you provide examples of recent developments in the market?
February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction. It is to cover patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Europe Sodium-glucose Cotransporter 2 Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Europe Sodium-glucose Cotransporter 2 Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Europe Sodium-glucose Cotransporter 2 Industry?
To stay informed about further developments, trends, and reports in the Europe Sodium-glucose Cotransporter 2 Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
